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Background: To investigate the risk factors for vaginal infections and antimicrobial suscep-
tibilities of vaginal microorganisms among women who experienced preterm birth (PTB), 
we compared the prevalence of vaginal microorganisms between women who experienced 
preterm labor (PTL) without preterm delivery and spontaneous PTB. 
Methods: Vaginal swab specimens from 126 pregnant women who experienced PTL were 
tested for group B streptococcus (GBS), Mycoplasma hominis, Mycoplasma genitalium, 
Ureaplasma urealyticum, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonor-
rhoeae, Treponema pallidum, herpes simplex virus (HSV) I and II, and bacterial vaginosis. 
A control group of 91 pregnant women was tested for GBS. Antimicrobial susceptibility 
tests were performed for GBS, M. hominis, and U. urealyticum. 
Results: The overall detection rates for each microorganism were: U. urealyticum, 62.7%; 
M. hominis, 12.7%; GBS, 7.9%; C. trachomatis, 2.4%; and HSV type II, 0.8%. The coloni-
zation rate of GBS in control group was 17.6%. The prevalence of GBS, M. hominis, and 
U. urealyticum in PTL without preterm delivery and spontaneous PTB were 3.8% and 
8.7% (relative risk [RR], 2.26), 3.8% and 17.3% (RR, 4.52), and 53.8% and 60.9% (RR, 
1.13), respectively, showing no significant difference between the 2 groups. The detection 
rate of M. hominis by PCR was higher than that by culture method (11.1% vs. 4.0%, P= 
0.010). The detection rates of U. urealyticum by PCR and culture method were 16.7% and 
57.1%, respectively. 
Conclusions: There was no significant difference in the prevalence of GBS, M. hominis, and 
U. urealyticum between the spontaneous PTB and PTL without preterm delivery groups. 
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INTRODUCTION
The complications of preterm birth (PTB) cause approximately 
70% of neonatal deaths and nearly half of all long-term neuro-
logical morbidity [1, 2]. PTB could be categorized by its clinical 
presentation: spontaneous preterm labor (PTL) leading to spon-
taneous PTB (S-PTB), preterm premature rupture of the mem-
branes (PPROM), and medically induced PTB (M-PTB) due to 
maternal or fetal complications [3]. However, not all contributory 
causes of S-PTB have been identified, and the healthcare sys-
tem is unable to target and manage relevant risk factors appro-
priately [4]. 
  Intrauterine infection has been proposed as one of the most 
important risk factors for complications in pregnancy, such as 
premature rupture of membrane, PTL, PTB, and perinatal in-
fections. Microorganisms may gain access to the amniotic cavity 
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and the fetus through the following pathways: 1) ascending from 
the vagina and the cervix; 2) hematogenous dissemination through 
the placenta (transplacental infection); 3) retrograde seeding 
from the peritoneal cavity through the fallopian tubes; and 4) 
accidental introduction at the time of invasive procedures such 
as amniocentesis, percutaneous fetal blood sampling, chorionic 
villous sampling, or shunting [5]. Most studies on detection of 
infection in patients who underwent PTL and preterm delivery 
have focused on microbial invasion of the amniotic cavity, which 
is normally sterile. Therefore, the isolation of any microorganism 
from the amniotic fluid constitutes evidence of microbial inva-
sion. The most common pathway of intrauterine infection is the 
ascending route [6]. 
  Although colonization of the maternal genital tract by specific 
organisms has been inconsistently associated with S-PTB and/
or PPROM, some infections have been consistently associated 
with preterm delivery [7]. It has been hypothesized that screen-
ing for and treatment of common vaginal infections would re-
duce the rate of PTB among affected women [8].
  The microorganisms associated with PTL without preterm de-
livery (PTL-WO), S-PTB, and PPROM are as follows: Treponema 
pallidum, Neisseria gonorrhoeae, group B streptococcus (GBS), 
Ureaplasma urealyticum, Mycoplasma hominis, Chlamydia tra-
chomatis, Trichomonas vaginalis, Gardnerella vaginalis, Bacte-
roides spp., and peptostreptococci [7, 9]. However, it is difficult 
to assess the extent of the causal relationship between infection 
and S-PTB because the maternal genital colonization rates by 
microorganisms differ according to race, gestational age, geo-
graphical variation, and investigators [2, 7, 9]. Moreover, it is not 
known how and when bacteria invade the uterus and whether 
additional (as yet undocumented) infections by viruses, proto-
zoa, or bacteria other than those mentioned above are involved 
in PTB [9]. 
  The purpose of this study was to determine the prevalence 
and antimicrobial susceptibilities of vaginal microorganisms iso-
lated from Korean women who experienced PTL-WO and S-PTB. 
Finally, we sought to identify the microorganisms that were po-
tential risk factors for PTB. 
METHODS
1. Study population
The study population consisted of 126 pregnant women who ex-
perienced PTL and a control group of 91 pregnant women, with 
no history of PTL or preterm delivery and who underwent rou-
tine prenatal care, admitted to the Wonju Christian Hospital be-
tween August 2008 and July 2009. The patients were divided 
into the following 3 groups according to the type of complica-
tions during pregnancy: 1) PTL-WO (N=26), 2) S-PTB (N=69), 
and 3) M-PTB (N=31). M-PTB was defined as PTB with risk 
factors such as spontaneous rupture of membranes, anomalies 
of conception, malformations of the fetus, overdistended uterus, 
hydramnios, multiple gestations, fetal death, cervical incompe-
tency, uterine anomalies, retained intrauterine device, serious 
maternal disease, pre-eclampsia, gestational diabetes mellitus, 
gestational hypertension, and active systemic infection. This 
study protocol was approved by the Institutional Review Board 
of Yonsei University Wonju College of Medicine. 
2. Genital microorganisms
1) Culture and antimicrobial susceptibility test for GBS 
Swab specimens from the vagina, anorectum, and urethral ori-
fice of pregnant women were placed in selective Todd-Hewitt 
broth (S-THB) and new Granada plate and tube medium made 
in the laboratory [10] and in new Granada medium purchased 
from bioMérieux (Marcy-l’Etoile, France) for 18-24 hr in 5% CO2 
atmosphere at 35°C. The colonies exhibiting orange coloration 
on new Granada tube or plate medium and/or exhibiting growth 
turbidity in S-THB were subcultured on 5% sheep blood agar 
and were identified using Streptex group B Streptococcus re-
agent (Wellcome Diagnostics, Dartford, England). Susceptibility 
to clindamycin, erythromycin, chloramphenicol, levofloxacin, 
penicillin, ceftriaxone, and vancomycin was tested using the Mi-
croScan
® MICroSTREP plus panel (Siemens Healthcare Diag-
nostics, Sacramento, CA, USA). The panel was inoculated using 
the Renok hydrator/inoculator, which delivered 115 µL of Muel-
ler-Hinton broth with 3% lysed horse blood to each well. After 
inoculation with 0.5 McFarland standard bacterial suspension, 
the panels were incubated at 35°C in ambient air for 20 to 24 hr 
and read using the MicroScan
® WalkAway System (Siemens 
Healthcare Diagnostics). 
2)     Culture and antimicrobial susceptibility test for M. hominis and 
U. urealyticum
Vaginal swab samples for Mycoplasma IST 2 (bioMérieux) test 
were obtained from each pregnant woman; the test was per-
formed according to the manufacturer’s instructions. The My-
coplasma IST 2 test contains strips that indicate the presence or 
absence of M. hominis and U. urealyticum, and provide addi-
tional information on antibiotic susceptibility to tetracycline, dox-
ycycline, erythromycin, clarithromycin, azithromycin, josamycin, 
ciprofloxacin, ofloxacin, and pristinamycin. One strip was placed Choi SJ, et al.
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directly into R1 tubes (transport medium) and subsequently de-
livered to the clinical microbiology laboratory for the identifica-
tion of both M. hominis and U. urealyticum and for the determi-
nation of antimicrobial susceptibility. Swabs in the R1 transport 
medium were processed according to the manufacturer’s in-
structions. They were mixed rapidly by vortexing, and then 3 mL 
of R1 was used to rehydrate the lyophilized growth medium R2 
(provided in the Mycoplasma IST-2 kit). A Mycoplasma IST strip, 
consisting of 22 wells, was then inoculated with the rehydrated 
R2 growth medium (55 μL per well, overlaid with 2 drops of 
mineral oil). From the R2 positive tube, 0.1 mL was also inocu-
lated onto A7 Mycoplasma agar plates (BioMérieux) and incu-
bated at 37˚C in an atmosphere of 5% CO2 to evaluate charac-
teristic colony morphology. All media and the inoculated strip 
were incubated at 37˚C in a CO2 incubator and monitored for 
color changes. The results were interpreted after 24 and 48 hr 
of incubation [11]. Wells 1-5 provided information on the pres-
ence or absence of M. hominis and U. urealyticum, with an es-
timate of the density of each organism (above, below, or equal 
to 10
4 colony-forming units [CFUs]). The antimicrobial suscepti-
bility test was performed when the colony count for each organ-
ism was ≥10
4 CFU/mL. 
3) Multiplex PCR for genital microorganisms
Samples for multiplex PCR were obtained from the posterior 
vaginal fornix by swabbing with a cytobrush. The swab was 
rinsed in a transport tube containing PCR buffer (phosphate-
buffered saline solution, pH 7.4, without calcium chloride and 
magnesium chloride; GibcoBRL, Grand Island, NY, USA). T. 
vaginalis, M. hominis, Mycoplasma genitalium, U. urealyticum, 
C. trachomatis, N. gonorrhoeae, T. pallidum, herpes simplex vi-
rus (HSV) I, and HSV II were simultaneously detected using the 
Seeplex
® STD6B ACE Detection kit (Seegene, Seoul, Korea). The 
swabbed sample was briefly vortexed and then centrifuged at 
3,000 rpm for 20 min. After centrifugation, the mixture of sample 
pellet, proteinase K (Boehringer Mannheim, Mannheim, Ger-
many), and buffer solution (10 mM Tric HCl, pH 8.3, 50 mM KCl, 
0.1 mg/mL gelatin, 0.45% NP40, and 0.45% Tween 20) was in-
cubated at 56˚C for more than 3 hr. The pellet was resuspended 
with phenol-chloroform, sodium acetate, and ethanol and incu-
bated on ice for 30 min. Then, the DNA was extracted by cen-
trifugation at room temperature for 5 min at 14,000 rpm, and the 
final pellet was frozen at -20˚C. The extracted DNA was washed 
with 70% ethanol and resuspended in sterile distilled water be-
fore using it for multiplex PCR. Multiplex PCR was performed 
using the method described by Kim et al. [12]. 
4)     Wet mount, Gram staining, and routine culture of vaginal  
specimens
Vaginal samples obtained using sterile cotton-tipped swabs were 
sent to the laboratory in transport medium. In the laboratory, the 
samples were aliquoted into 2 separate tubes: one for direct wet-
mount microscopic examination and the other for Gram staining 
and subsequent inoculation onto blood and MacConkey agar 
plates. Examination of wet preparations was performed to rule 
out the presence of T. vaginalis and to detect the presence of 
yeasts. Gram staining was used to detect the presence of yeasts, 
inflammatory cells, and possible pathogenic microorganisms 
and to diagnose bacterial vaginosis (BV) by observing the “clue 
cells”.
3. Statistical analysis
Statistical analysis was performed using the chi-square or Fisher’s 
exact test with PASW Statistics 18 (SPSS Inc., Chicago, IL, USA). 
P values <0.05 were considered statistically significant. Relative 
risk ratio analysis was performed to evaluate if M. hominis, U. 
urealyticum, and GBS were independent risk factors for the de-
velopment of S-PTB from PTL-WO. 
RESULTS
1.     The prevalence of genital microorganisms in different 
types of pregnancy complications
The colonization rates of GBS in the PTL-WO, S-PTB, M-PTB, 
and control groups were 3.8%, 8.7%, 9.7%, and 17.6%, respec-
tively. Although the colonization rate of GBS in the S-PTB group 
was more than 2 times that in the PTL-WO group, there was no 
statistically significant difference between the 2 groups (relative 
risk ratio [RR], 2.26; 95% confidence interval [CI], 0.29-17.89; 
P>0.05). The colonization rate of GBS in the control group was 
much higher than that in the patient groups, although there was 
no statistically significant difference among the groups. The de-
tection rates of M. hominis in the PTL-WO, S-PTB, and M-PTB 
groups were 3.8%, 17.3%, and 9.7%, respectively. The preva-
lence of M. hominis in the S-PTB group was higher than that in 
the PTL-WO group; however, there was no statistically significant 
difference between the 2 groups (RR, 4.52; 95% CI, 0.62-33.06; 
P=0.105). The detection rates of M. hominis by PCR and cul-
ture were as follows: 3.8% vs. 3.8% in the PTL-WO group, 14.4% 
vs. 5.7% in the S-PTB group, and 9.7% vs. 0% in the M-PTB 
group. The detection rates of U. urealyticum in the PTL-WO, S-
PTB, and M-PTB groups were 53.8%, 60.9%, and 74.2%, re-
spectively. The prevalence of U. urealyticum in the S-PTB group Choi SJ, et al.
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was higher than that in the PTL-WO group; however, there was 
no statistically significant difference between the 2 groups (RR, 
1.13; 95% CI, 0.76-1.69; P>0.05). The detection rates of U. ure-
alyticum by PCR and culture were as follows: 19.2% vs. 42.3% 
in the PTL-WO group, 17.4% vs. 58.0% in the S-PTB group, and 
13.0% vs. 67.8% in the M-PTB group. The detection rates of C. 
trachomatis in the PTL-WO, S-PTB, and M-PTB groups were 
7.7%, 1.4%, and 0%, respectively. The detection rates of mo-
nilia were 7.7% in the PTL-WO group, 2.9% in the S-PTB group, 
and 3.2% in the M-PTB group. None of the other microorgan-
isms/viruses, HSV I, M. genitalium, T. vaginalis, N. gonorrhoeae, 
and T. pallidum were detected in this study (Table 1). 
2. Antimicrobial susceptibility test
The resistance rates of clindamycin, erythromycin, chloram-
phenicol, and levofloxacin in 26 GBS isolates were 11.5%, 11.5%, 
3.8%, and 7.7%, respectively. All isolates of GBS were suscepti-
ble to penicillin, ceftriaxone, and vancomycin. The cultures of M. 
hominis derived from 2 patients were resistant to erythromycin, 
tetracycline, ciprofloxacin, ofloxacin, clarithromycin, and azithro-
mycin and susceptible to josamycin and pristinamycin. The M. 
hominis culture from 1 of the 2 patients was susceptible to dox-
ycycline. The resistance rates to ciprofloxacin, ofloxacin, tetracy-
cline, azithromycin, erythromycin, clarithromycin, and doxycy-
cline for 56 U. urealyticum isolates were 96.4%, 55.4%, 19.6%, 
12.5%, 8.9%, 7.1%, and 7.1%, respectively. All the U. urealyti-
cum isolates were susceptible to josamycin and pristinamycin 
(Table 2). 
DISCUSSION
The causal relationship between abnormalities in vaginal flora 
during pregnancy and PTB has gained a lot of attention [13-16]. 
Although this phenomenon is relatively common, the patho-
genic mechanism that leads to S-PTB is still poorly understood. 
It is particularly difficult to define abnormal genital tract flora in 
pregnant women. The pathogenic role of specific microorgan-
isms in the vagina as risk factors for S-PTB varies according to 
the investigators, because microorganisms commonly found in 
the lower genital tract are those that are most frequently isolated 
from patients with intrauterine infections. The colonization rate 
of microorganisms in the vagina could be affected by not only 
technical factors, such as detection method and sampling site, 
but also internal and external factors of each individual [17]. 
Possible racial/ethnic differences in the composition of the nor-
mal vaginal microflora also exist. Usui et al. [16] reported that 
absence of vaginal lactobacilli was a better predictor of S-PTB at 
<33 weeks of gestation than the presence of M. hominis, but its 
sensitivity and positive predictive value were no more than 28% 
and 25%, respectively. Breugelmans et al. [15] reported that 
there was no significant correlation between the presence of ab-
normal vaginal flora and S-PTB, and the risk of S-PTB increased 
when Ureaplasma species was associated with an abnormal 
vaginal flora. 
  Although BV has been considered a risk factor for S-PTB, in-
vestigators have been unable to prove a consistent association 
Table 1. Prevalence of microorganisms isolated from the lower gen-
ital tract in pregnant women with different types of pregnancy com-
plications
Organisms 
Control 
group*
(N=91) 
Type of pregnancy complication
PTL-WO 
(N=26) 
PTB
Total 
(N=126) S-PTB
(N=69)
M-PTB
(N=31)
S. agalactiae  16 (17.6)  1 (3.8) 6 (8.7) 3 (9.7) 10 (7.9)
M. hominis 
PCR +, culture −  0  8 (11.6) 3 (9.7) 11 (8.7)
PCR +, culture + (<10
4) 0 1 (1.4) 0 1 (0.8)
PCR +, culture + (≥10
4)  1 (3.8) 1 (1.4) 0 2 (1.6)
PCR −, culture + (<10
4) 0 2 (2.9) 0 2 (1.6)
Subtotal 1 (3.8) 12 (17.3) 3 (9.7) 16 (12.7)
U. urealyticum 
PCR +, culture −  3 (11.5) 2 (2.9) 2 (6.5) 7 (5.6)
PCR +, culture + (≥10
4)  2 (7.7) 10 (14.5) 2 (6.5) 14 (11.1)
PCR −, culture + (<10
4) 3 (11.5) 9 (13.0) 4 (12.9) 16 (12.7)
PCR −, culture + (≥10
4)  6 (23.1) 21 (30.5) 15 (48.4)  42 (33.3)
Subtotal 14 (53.8) 42 (60.9) 23 (74.2) 79 (62.7)
C. trachomatis by PCR 2 (7.7) 1 (1.4) 0 3 (2.4)
HSV II by PCR  0 1 (1.4) 0 1 (0.8)
HSV I by PCR  0 0 0 0
M. genitalium by PCR 0 0 0 0
T. vaginalis by PCR and WM 0 0 0 0
N. gonorrhoeae by PCR 0 0 0 0
T. pallidum by PCR 0 0 0 0
Monilia  2 (7.7) 2 (2.9) 1 (3.2) 5 (4.0)
Clue cells 0 1 (1.4) 0 1 (0.8)
*The control group consisted of pregnant women with no history of preterm 
labor or delivery, who underwent routine prenatal care, and were tested for 
only GBS. 
Abbreviations: PTL-WO, preterm labor without preterm delivery; PTB, pre-
term birth; S-PTB, spontaneous PTB; M-PTB, medically induced PTB; +, 
positive; −, negative; HSV, herpes simplex virus; WM, wet mount microscop-
ic examination.Choi SJ, et al.
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between BV and S-PTB [18]. In this study, clue cells were de-
tected in only 1.4% of the S-PTB group, which suggests that BV 
is not associated with S-PTB. Possible explanations for our re-
sult are that BV is diagnosed mostly in the first trimester and the 
prevalence decreases in the second and third trimesters [18] 
and that the relationship of BV with S-PTB may vary according 
to the diagnostic criteria for the detection of BV. 
  U. urealyticum and M. hominis are among the organisms 
most frequently isolated from both placental membranes and 
amniotic fluid in patients with PPROM and those with PTL-WO 
[19-22]. Both organisms can initiate the synthesis of prostaglan-
dins, resulting in S-PTB [9]. Nevertheless, there is much debate 
regarding whether genital mycoplasmas are pathogenic or sim-
ply frequent colonizers of the genital tract [14, 15, 20, 21]. The 
traditional view has been that genital mycoplasmas are part of 
the vaginal microflora in many women, and their presence in 
the lower genital tract, unlike their presence in the upper genital 
tract, has not been associated with an increased risk of S-PTB 
[22, 23]. 
  Studies on the exact colonization rates of genital mycoplas-
mas should be performed to elucidate whether genital myco-
plasmas are pathogenic. In our study population, overall detec-
tion rates of M. hominis and U. urealyticum in the vagina were 
12.7% and 62.7%, respectively. The detection rate of M. homi-
nis by PCR was higher than that by the culture method, while 
the detection rate of U. urealyticum by the culture method was 
higher than that by PCR. Possible explanations include lower 
sensitivity of the specific primer used in this study for the detec-
tion of U. urealyticum and/or false positive detection of Urea-
plasma parvum by the culture method. A new species U. par-
vum (formerly biovar 1 of U. urealyticum serovars 1, 3, 6, and 
14) was identified as U. urealyticum by using the Mycoplasma 
IST 2 test [24]. Lee et al. [14] reported that the prevalence of U. 
urealyticum was 28.6% (279/977) and that of M. hominis was 
3.7% (36/977) in a vaginal fluid culture for genital mycoplasmas 
in pregnant women and that it was not associated with an in-
creased risk for S-PTB. In contrast, Kafetzis et al. [25] reported 
that vaginal colonization with Ureaplasma species is associated 
with S-PTB because the rate of vertical transmission of Urea-
plasma in mothers who experienced PTB was higher than that 
in mothers who experienced full-term delivery (33% vs. 17%). 
However, vaginal Ureaplasma colonization occurred among 
36.5% of the mothers who experienced S-PTB and among 38% 
of the mothers who experienced full-term delivery. In this study, 
the RR of M. hominis and U. urealyticum in S-PTB to that in 
PTL-WO was 4.52 and 1.13, respectively, but these results were 
not statistically significant. Ureaplasma spp. can persist for weeks 
in the upper genital tract before spontaneous PTL or membrane 
Table 2. Antimicrobial resistance rates (%) of GBS, Mycoplasma hominis, and Ureaplasma urealyticum in pregnant women with different 
types of pregnancy complications
Antimicrobials
Control
Group* PTL-WO S-PTB M-PTB
GBS (N=16) GBS (N=1) MHO
† (N=1) UUR
† (N=8) GBS (N=6) MHO
† (N=1) UUR
† (N=31) GBS (N=3) UUR
† (N=17)
Clindamycin  6.3 0  16.7  33.3 
Erythromycin  6.3 100 100  12.5 16.7 100 6.5 0  11.8
Chloramphenicol  0  100  0 0 
Levofloxacin  0 100 0  33.3
Tetracycline 100 12.5  100 16.1 17.7
Ciprofloxacin 100  100 100 96.8 94.1
Ofloxacin 100  62.5  100 54.8 52.9 
Clarithromycin 100 12.5  100  6.5 5.9
Josamycin 0  0 0 0  0 
Pristinamycin 0 0 0 0  0 
Azithromycin 100 12.5 100 12.9  11.8 
Doxycycline 100 0 0 6.5  11.8 
*The control group consisted of pregnant women with no history of preterm labor or delivery, who underwent routine prenatal care, and were tested for only 
GBS; 
†Antimicrobial susceptibility test was performed if the colony count of the organism was ≥10
4 CFU/mL. 
Abbreviations: PTL-WO, preterm labor without preterm delivery; S-PTB, spontaneous preterm birth; M-PTB, medically induced PTB; GBS, group B strepto-
coccus; MHO, Mycoplasma hominis; UUR, Ureaplasma urealyticum.Choi SJ, et al.
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rupture initiates S-PTB. Among the pregnant women who show 
Ureaplasma spp. and/or M. hominis colonization, only a small 
group will experience an ascending infection. The reason why 
this microorganism sometimes causes an ascending infection is 
not yet understood. There might be other associated factors that 
increase the capacity of the microorganism to invade the uterine 
cavity. These factors might include the host immune system, the 
virulence of the microorganisms, or local factors favoring the in-
vasion of genital mycoplasmas. 
  GBS is detected in the vagina and rectum of 10-30% of preg-
nant women as normal flora, but it has emerged as a major 
pathogen for a variety of bacterial infections among pregnant 
women, non-pregnant adults, and elderly patients [26]. Garland 
et al. [27] reported that GBS is considered a risk factor for S-
PTB because of its association with asymptomatic bacteriuria. 
However, when it colonizes the lower genital tract alone, it is not 
thought to promote preterm delivery. In this study, the RR of 
GBS in S-PTB was 2.26 (P<0.05), which suggests that GBS was 
not an independent risk factor for the development of S-PTB 
from PTL-WO. 
  N. gonorrhoeae and C. trachomatis are rarely implicated in 
uterine or fetal infection before the rupture of the membranes; 
however, both may have an adverse effect on pregnancy, thus 
increasing the risk for PTL [9]. N. gonorrhoeae has been shown 
to be present in approximately 1% of pregnant women and if 
left untreated, leads to a 2-5% RR of S-PTB [28]. In our study, 
the prevalence of C. trachomatis and N. gonorrhoeae by PCR 
was 2.4% and 0%, respectively; HSV I, M. genitalium, T. vagina-
lis, and T. pallidum were not detected using PCR. 
  Antibiotic administration to patients with PPROM is associ-
ated with prolongation of pregnancy and reduction in the rate of 
clinical chorioamnionitis and neonatal sepsis. The benefit has 
not been demonstrated in patients with PTL-WO and intact 
membranes. Major efforts are required to determine why some 
women develop an ascending intrauterine infection and others 
do not and which interventions reduce the deleterious effect of 
systemic fetal inflammation. According to a large randomized 
study, erythromycin treatment of pregnant women with U. urea-
lyticum vaginal colonization does not confer any advantage in 
terms of reduction in the rate of S-PTB [29]. In this study, the 
resistance rate of erythromycin in U. urealyticum was 8.9%, 
while that of ciprofloxacin was 96.4%. 
  Our results demonstrated that genital mycoplasmas and GBS 
in the lower genital tract were not risk factors for the develop-
ment of S-PTB from PTL-WO, although detection rates of those 
organisms in S-PTB were higher than those in PTL-WO. Differ-
ences in host response to the presence of genital mycoplasmas 
and GBS, rather than the mere presence of the bacteria them-
selves, may contribute to an increased risk of S-PTB. 
  The limitations of this study were that only a small number of 
PTL patients were enrolled and that the control group that did 
not experience PTL or PTB was only tested for GBS coloniza-
tion. Additional large-scale studies on the colonization rates of 
GBS, M. hominis, and U. urealyticum in normal preterm women 
without labor or delivery are required to elucidate the pathogenic 
roles of these organisms in PTL-WO and S-PTB. 
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